• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Oncology/Infection
  • A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults with Refractory CD22+ Acute Lymphoblastick Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL)

Disease
acute lymphocytic leukaemia, non-Hodgkin's lymphoma
Drug Name
CAT-8015
Sponsor
MedImmune
Drug Status
In Development
Phase
I
Start Date
Sep 29, 2008
Study Name
CAT-8015-1004
Study Id
CAT-8015-1004
ClinicalTrials.gov ID
NCT00659425
Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013